Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Asia Diagnostics Summit 2018

James Lee's Biography



James Lee, Helen C. Kurtz Professor of Chemical and Biomolecular Engineering, The Ohio State University

Dr. Lee is the Emeritus Helen C. Kurtz Professor of Chemical and Biomolecular Engineering at The Ohio State University (OSU) and the founder of Nanomateial Innovation Ltd. (NIL). He founded and led the NSF Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymer Biomedical Devices (CANPBD) at OSU. He received a BS degree in chemical engineering from National Taiwan University and a Ph.D. degree in chemical engineering from University of Minnesota. Dr. Lee has more than 400 refereed journal publications, 30 patents and invention disclosures, and 15 book chapters. He was elected as the Fellow of American Institute for Medical and Biological Engineering in 2006. Dr. Lee received the 2008 Malcolm E. Pruitt Award from Council of Chemical Research and 2010 International Award from the Society of Plastic Engineers. Dr. Lee’s research is on biomaterials-based micro/nanotechnologies for drug/gene delivery, disease diagnosis, and cell reprogramming for regenerative medicine.

James Lee Image

Using Molecular Beacons for Extracellular Vesicles and CTC-based Cancer Detection

Tuesday, 6 November 2018 at 11:30

Add to Calendar ▼2018-11-06 11:30:002018-11-06 12:30:00Europe/LondonUsing Molecular Beacons for Extracellular Vesicles and CTC-based Cancer DetectionAsia Diagnostics Summit 2018 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com

Given their role in fundamental tumor biology, circulating non-coding RNAs and coding RNAs have emerged as potential biomarkers for cancer detection. Extracellular RNAs have been found to be stable in blood and other bodily fluids, partially attributable to their encapsulation within cell-secreted extracellular vesicles (EVs). The current method for EV analysis uses either PCR, next generation sequencing and/or hybridization microarray to identify the presence of RNA targets. These technologies involve breaking open all EVs in the sample to mix their contents, so they can only provide averaged information. Since EVs come from multiple cell sources, RNA targets of cancer cells derived EVs are diluted in these analyses. We have developed facile and inexpensive biochip technologies to detect target RNA using advanced molecular beacons designs and nanoparticles. These biochips technologies have been successfully applied to various cancer diagnosis in liquid biopsy. The molecular beacons can also be used to detect RNA targets in circulating tumor cells (CTCs) in blood.


Add to Calendar ▼2018-11-05 00:00:002018-11-06 00:00:00Europe/LondonAsia Diagnostics Summit 2018Asia Diagnostics Summit 2018 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com